C5ORF34 antibody (AA 1-100) (Biotin)

Catalog No. ABIN1701100

Product Details anti-C5ORF34 Antibody (Biotin)

Target: C5ORF34 (Chromosome 5 Open Reading Frame 34 (C5ORF34))

Binding Specificity: AA 1-100

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This C5ORF34 antibody is conjugated to Biotin

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Cross-Reactivity: Human

Predicted Reactivity: Mouse,Rat,Dog,Pig,Horse

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human C5orf34

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C for 12 months.

Expiry Date: 12 months

Target Details for C5ORF34

Target: C5ORF34 (Chromosome 5 Open Reading Frame 34 (C5ORF34))

Alternative Name: C5orf34 (C5ORF34 Products)

Synonyms: chromosome 5 open reading frame 34 antibody, C5orf34 antibody

Background:

Synonyms: C5orf34, CE034_HUMAN, FLJ32363, Uncharacterized protein C5orf34.

Background: C5orf34 is a With 181 million base pairs encoding around 1,000 genes, chromosome 5 is about 6 % of human genomic DNA. It is associated with Cockayne syndrome through the ERCC8 gene and familial adenomatous polyposis through the adenomatous polyposis coli (APC) tumor suppressor gene. Treacher Collins syndrome is also chromosome 5 associated and is caused by insertions or deletions within the TCOF1 gene. Deletion of the p arm of chromosome 5 leads to Cri du chat syndrome. Deletion of 5q or chromosome 5 altogether is common in therapy-related acute myelogenous leukemias and myelodysplastic syndrome. The C5orf34 gene product has been provisionally designated C5orf34 pending further characterization.